Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.93B |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$297M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$219M |
| 4 |
Johnson & Johnson
JNJ
|
+$210M |
| 5 |
iShares MSCI China ETF
MCHI
|
+$207M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
INP
iPath ETNs Linked to the MSCI India Total Return Index
INP
|
+$1.2B |
| 2 |
Bausch Health
BHC
|
+$484M |
| 3 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$333M |
| 4 |
AT&T
T
|
+$279M |
| 5 |
LO
LORILLARD INC COM STK
LO
|
+$255M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 6.63% |
| 2 | Technology | 4.94% |
| 3 | Financials | 3.76% |
| 4 | Energy | 3.19% |
| 5 | Industrials | 2.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5801
Biglari Holdings Class B
BH
$1.25B
| $13K | ﹤0.01% |
48
-30
| -38% | -$7.8K |
|
5802
Coherus Oncology
CHRS
$217M
| $13K | ﹤0.01% |
452
+244
| +117% | +$6.17K |
|
5803
Cohen & Steers
CNS
$4.23B
| $13K | ﹤0.01% |
388
-195
| -33% | -$7.36K |
|
5804
Coca-Cola Consolidated
COKE
$12.5B
| $13K | ﹤0.01% |
890
-510
| -36% | -$6.13K |
|
5805
Cavco Industries
CVCO
$4.22B
| $13K | ﹤0.01% |
167
-102
| -38% | -$7.31K |
|
5806
Invesco DB Base Metals Fund
DBB
$312M
| $13K | ﹤0.01% |
919
+683
| +289% | +$10.5K |
|
|
DX
5807
Dynex Capital
DX
$3.15B
| $13K | ﹤0.01% |
584
-200
| -26% | -$4.75K |
|
5808
8x8 Inc
EGHT
$269M
| $13K | ﹤0.01% |
1,687
-973
| -37% | -$8.59K |
|
5809
Employers Holdings
EIG
$908M
| $13K | ﹤0.01% |
610
-948
| -61% | -$23.2K |
|
5810
iShares MSCI South Africa ETF
EZA
$547M
| $13K | ﹤0.01% |
196
-20,667
| -99% | -$1.4M |
|
5811
Franklin Covey
FC
$242M
| $13K | ﹤0.01% |
622
-1,603
| -72% | -$31.3K |
|
5812
ICF International
ICFI
$1.46B
| $13K | ﹤0.01% |
373
-227
| -38% | -$8.54K |
|
5813
Standard BioTools
LAB
$340M
| $13K | ﹤0.01% |
552
-288
| -34% | -$9.09K |
|
5814
Larimar Therapeutics
LRMR
$397M
| $13K | ﹤0.01% |
31
-18
| -37% | -$7.53K |
|
5815
Materion
MTRN
$4.39B
| $13K | ﹤0.01% |
385
-234
| -38% | -$9.02K |
|
5816
CALL
Nice
NICE
$5.79B
| $13K | ﹤0.01% |
200
-100
| -33% | -$6.31K |
|
5817
Navigator Holdings
NVGS
$1.38B
| $13K | ﹤0.01% |
720
| – | – |
|
5818
Quanex
NX
$819M
| $13K | ﹤0.01% |
649
-397
| -38% | -$7.65K |
|
5819
Phibro Animal Health
PAHC
$1.47B
| $13K | ﹤0.01% |
334
-108
| -24% | -$3.73K |
|
|
PRO
5820
DELISTED
PROS Holdings
PRO
| $13K | ﹤0.01% |
596
-8,385
| -93% | -$183K |
|
5821
Tempest Therapeutics
TPST
$13.7M
| – | – |
0
| – | – |
|
5822
TTM Technologies
TTMI
$12B
| $13K | ﹤0.01% |
1,465
-11,141
| -88% | -$108K |
|
5823
CALL
Zumiez
ZUMZ
$332M
| $13K | ﹤0.01% |
500
-800
| -62% | -$24.6K |
|
|
5824
Zumiez
ZUMZ
$332M
| $13K | ﹤0.01% |
495
-4,016
| -89% | -$123K |
|
|
TBRG
5825
DELISTED
TruBridge
TBRG
| $13K | ﹤0.01% |
256
-2,715
| -91% | -$146K |
|
Similar funds
Barclays's Q2 2015 Portfolio in Review
As of Q2 2015, Barclays held 7,557 positions worth $89.1B, up 2.7% from $86.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Barclays's Q2 2015 filing shows 425 new, 2,570 increased, 3,770 reduced and 450 closed positions. Its largest new stake was Element Solutions: 801,973 shares worth $20M. The largest sale was iPath ETNs Linked to the MSCI India Total Return Index, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 6.6% of assets, down from 7.6% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2015 buy was Element Solutions: 801,973 shares worth $20M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q2 2015, an estimated $2.93B increase.
- Barclays's biggest Q2 2015 reduction was Bausch Health, cutting an estimated $484M.
- Barclays fully exited iPath ETNs Linked to the MSCI India Total Return Index in Q2 2015, selling an estimated $1.2B.
- Barclays's ten largest holdings make up 31% of its $89.1B portfolio in Q2 2015.
- Barclays opened 425 new positions and closed 450 in Q2 2015.
- Barclays's portfolio value rose 2.7% quarter-over-quarter to $89.1B.
Based on Barclays's 13F filing for Q2 2015, filed 14 Aug 2015.